Get the Stockscreener App
148.93
0.60%
-0.90
Insulet Corp stock is traded at $148.93, with a volume of 1.04M.
It is down -0.60% in the last 24 hours and up +12.11% over the past month.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
See More
Previous Close:
$149.83
Open:
$149.28
24h Volume:
1.04M
Relative Volume:
0.78
Market Cap:
$10.33B
Revenue:
$2.90B
Net Income/Loss:
$302.80M
P/E Ratio:
34.66
EPS:
4.2965
Net Cash Flow:
$387.80M
1W Performance:
+0.55%
1M Performance:
+12.11%
6M Performance:
-6.93%
1Y Performance:
-52.90%
1-Day Range:
$0.00
$0.00
1-Week Range:
$145.00
$150.74
52-Week Range:
$126.40
$354.88
Insulet Corp Stock (PODD) Company Profile
Name
Insulet Corp
Sector
Industry
Phone
978-600-7000
Address
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corp
|
148.93 | 10.33B | 2.90B | 302.80M | 387.80M | 4.2965 |
ABT
Abbott Laboratories
|
102.64 | 177.61B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.78 | 121.24B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
304.00 | 116.61B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
42.43 | 61.49B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
91.78 | 52.90B | 6.30B | 1.07B | 1.09B | 1.8406 |
Insulet Corp Stock (PODD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-26 | Initiated | Barclays | Equal Weight |
| Aug-06-26 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-06-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Aug-06-26 | Downgrade | Truist | Buy → Hold |
| Aug-06-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-28-26 | Resumed | UBS | Neutral |
| Jun-23-26 | Initiated | Deutsche Bank | Buy |
| May-20-26 | Resumed | William Blair | Outperform |
| Apr-24-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Apr-07-26 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-26 | Resumed | TD Cowen | Hold |
| Jan-12-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-16-25 | Initiated | Evercore ISI | Outperform |
| Nov-19-25 | Upgrade | UBS | Neutral → Buy |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Resumed | Oppenheimer | Outperform |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| May-13-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-29-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Mar-06-25 | Initiated | RBC Capital Mkts | Outperform |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-07-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-21-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-04-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-02-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-21-23 | Upgrade | Citigroup | Neutral → Buy |
| Aug-21-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-11-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-19-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Jul-28-20 | Initiated | Wells Fargo | Overweight |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-03-20 | Initiated | BofA/Merrill | Neutral |
| Mar-31-20 | Downgrade | Berenberg | Buy → Hold |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-10-19 | Initiated | CFRA | Sell |
| Oct-23-19 | Initiated | Stifel | Hold |
| Oct-18-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-14-19 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-04-19 | Downgrade | UBS | Buy → Neutral |
| Oct-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-06-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-10-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-06-19 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-20-18 | Initiated | Berenberg | Buy |
| Feb-22-18 | Reiterated | Barclays | Overweight |
| Jan-08-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Nov-03-17 | Upgrade | Canaccord Genuity | Hold → Buy |
| Sep-15-17 | Initiated | Barclays | Overweight |
View All
Insulet Corp Stock (PODD) Latest News
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth - Zacks Investment Research
Type 1 Diabetes, and Bentley, Taught Cooper Farrall How to Build Something Bigger Than Himself - Bentley University
Insulet's Quarterly Earnings Preview: What You Need to Know - Barchart.com
vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems - The Manila Times
Insulin Patch Pump Market to Reach US$ 5.53 Billion by 2035, - openPR.com
Insulet Corp (GOV.DU) stock major holders - Yahoo Finance Australia
Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman (PODD) Investigation: Bronstein, Ge - The National Law Review
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research
Full Fed. Circ. Won't Revive Insulet's $59M Trade Secrets Win - Law360
MONDAY INVESTOR DEADLINE: Insulet Corporation (PODD) Investors wi - The National Law Review
PODD Investors Have Opportunity to Lead Insulet Corporation Class - The National Law Review
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet Ordered to Defend Retirement Plan’s Target-Date Funds - Bloomberg Law News
Here's Why Insulet (PODD) is a Strong Growth Stock - Zacks Investment Research
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Insulet Corp. stock outperforms competitors despite losses on the day - MarketWatch
Insulet Launches Omnipod Discover Diabetes Data Platform Nationwide - Medical Product Outsourcing
Insulet’s Omnipod Discover platform sees full market release in US - Fierce Biotech
A Look at Insulet Corp (PODD) After 3.4% Gain -- GF Value $398.3 - GuruFocus
Insulet Stock Gains as Traders Weigh Bullish Analyst Stance Against a Depressed Share Price - Quiver Quantitative
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
PODD Maintains Buy Rating -- Price Target Lowered to $190 by Jef - GuruFocus
Insulet Launches Omnipod Discover Platform Across US - www.marketscreener.com
Insulet Launches Omnipod Discover Platform Across US - Yahoo Finance
Insulet launches Omnipod Discover data platform in U.S. By Investing.com - Investing.com South Africa
Insulet launches Omnipod Discover data platform in U.S. - Investing.com
Insulet launches Omnipod Discover data platform in the U.S. - StreetInsider
Insulet Announces Omnipod Discover Now Available in U.S. - Business Wire
Jefferies cuts Insulet stock price target on competition concerns - Investing.com
Insulet Corporation (PODD) PT Lowered to $190 at Jefferies - StreetInsider
Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman (PODD) Investors to Inquire about Securities Investigation - ACCESS Newswire
Form 4 Insulet Corporation For: 11 October By Investing.com - Investing.com South Africa
Leerink Partners Adjusts Insulet Price Target to $143 From $145 - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Insulet Q2FY26 Results: Revenue up 23% YoY, adjusted EPS rises 41.5% - scanx.trade
Insulet Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Insulet Corp Lobbying Profile, 2018 - OpenSecrets
Insulet stock gets a Barclays Hold rating with USD 150 target - AD HOC NEWS
Insulet Corporation (PODD) Stock Forecasts - Yahoo Finance
Insulet Corp Share PricePODD, RNS News, Articles, Quotes, & Charts (NASDAQ:PODD) - Proactive financial news
Barclays Starts Insulet Corporation (PODD) at Equalweight - StreetInsider
Barclays Starts Insulet Corporation (PODD) at Equalweight - StreetInsider
Form 4 Insulet Corporation For: 6 October By Investing.com - Investing.com India
Ascensia Diabetes Care Expands Strategic Alliance with Insulet Corporation by Signing Commercial Agreement - Lelezard
Form 4 Insulet Corporation For: 6 October By Investing.com - Investing.com South Africa
Insulet (PODD) CFO Flavia Pease has 1,882 shares withheld for vesting taxes at $130.79 each. - Stock Titan
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
PODD Should I Buy - Intellectia AI
Form 4 Insulet Corporation For: 2 October By Investing.com - Investing.com South Africa
Insulet Corp Stock (PODD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insulet Corp Stock (PODD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WEATHERMAN ELIZABETH H | Director |
Jun 03 '26 |
Buy |
144.20 |
3,450 |
497,490 |
10,352 |
| BORIO LUCIANA | Director |
Jun 03 '26 |
Proposed Sale |
143.26 |
418 |
59,885 |
0 |
| STONESIFER TIMOTHY C. | Director |
Jun 03 '26 |
Buy |
143.51 |
2,790 |
400,393 |
9,041 |
| BORIO LUCIANA | Director |
Jun 03 '26 |
Sale |
143.27 |
418 |
59,887 |
4,329 |
| MINOGUE MICHAEL R | Director |
Feb 25 '26 |
Buy |
246.23 |
2,030 |
499,847 |
17,483 |
| McEvoy Ashley | President and CEO |
Feb 20 '26 |
Buy |
239.35 |
4,300 |
1,029,205 |
13,916 |
| Frederick Wayne A.I. | Director |
Dec 15 '25 |
Proposed Sale |
293.09 |
1,851 |
542,500 |
0 |
| Frederick Wayne A.I. | Director |
Dec 15 '25 |
Sale |
293.09 |
1,851 |
542,510 |
2,158 |
| STONESIFER TIMOTHY C. | Director |
Dec 05 '25 |
Buy |
311.73 |
962 |
299,884 |
4,591 |
| Manea Dan | Former Officer |
Nov 26 '25 |
Proposed Sale |
326.64 |
4,475 |
1,461,716 |
0 |
1.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):